ALVO
NASDAQ · Biotechnology
Alvotech Sa
$3.81
+0.01 (+0.26%)
Open$3.83
Previous Close$3.80
Day High$3.86
Day Low$3.79
52W High$9.25
52W Low$2.94
Volume—
Avg Volume991.2K
Market Cap1.48B
P/E Ratio—
EPS$-0.28
SectorBiotechnology
Analyst Ratings
Buy
11 analysts
Price Target
+732.5% upside
Current
$3.81
$3.81
Target
$31.72
$31.72
$22.31
$31.72 avg
$46.94
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 791.51M | 415.23M | 133.98M |
| Net Income | 37.54M | 17.72M | 26.13M |
| Profit Margin | 4.7% | 4.5% | 19.5% |
| EBITDA | 160.98M | 80.23M | 43.53M |
| Free Cash Flow | — | — | 33.36M |
| Rev Growth | +90.6% | +90.6% | +20.0% |
| Debt/Equity | — | — | 0.40 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $246.04 | +0.89% | 118.6 | 430.95B |
| AMGN | Amgen Inc | $410.95 | +1.51% | 25.1 | 219.39B |
| GILD | Gilead Sciences Inc | $133.21 | +1.80% | — | 165.85B |
| VRTX | Vertex Pharmaceuticals Inc | $496.07 | +2.49% | 28.3 | 124.51B |
| REGN | Regeneron Pharmaceuticals | $784.36 | +1.59% | 18.4 | 79.53B |
| ALNY | Alnylam Pharmaceuticals Inc | $219.20 | +1.43% | 35.2 | 28.41B |